Introduction
kidney function, lenalidomide elimination is delayed and dosage adaptation is required [1] . Lenalidomide disposition was studied during classical dialysis sessions, and elimination was found to be significantly increased [2] . However, lenalidomide has never been investigated during high cutoff (HCO) dialysis, nowadays increasingly used in the management of renal failure caused by multiple myeloma. Dialyzers used for HCO dialysis having a higher permeability for substances in the molecular weight range of 15-45 kDa are implemented using longer (8 h), more frequent (daily) dialysis sessions and requires albumin substitution. Higher drug elimination may therefore occur compared to classical intermittent hemodialysis. We report here the pharmacokinetic profile of lenalidomide during HCO dialysis in a patient with multiple myeloma and advanced renal failure.
Methods

Case presentation
A 69-year-old woman (54.7 kg) known for progressive IgG kappa light-chain, stage III multiple myeloma (diagnosed 7 years ago) was hospitalized for acute renal failure requiring dialysis (GFR < 5 mL/min). Renal failure was caused by cast nephropathy (light chains deposition), confirmed by biopsy. HCO dialysis (Theralite™, Gambro Lundia AB, Lund, Sweden) was started on admission, 5 days a week, 8 h per session with an albumin substitution of 7 g/h and an average blood and dialysate flow of 300-350 and 500 mL/ min, respectively. Lenalidomide (Revlimid ® ) first cycle was started at the same time, in replacement of bortezomib, given over one year until then. We were concerned about a potential decrease in lenalidomide exposure during HCO dialysis and therefore increased lenalidomide dosage to 5 mg b.i.d. with one dose at the beginning and another one at the end of dialysis sessions (instead of 5 mg q.d. usually recommended in terminal renal failure [1] ).
The patient showed a good response to combined antitumor and purification treatment, with serum kappa free light chains decreasing from 7620 to 795 mg/L (sustained reduction, 89%) after the first cycle of lenalidomide. Major toxicity was not reported, but mild and reversible thrombocytopenia occurred after 14 days of treatment. Renal function unfortunately did not recover, and the patient was eventually switched to intermittent hemodialysis 2 months later.
Samples collection
We collected a set of blood samples to determine lenalidomide plasma levels during dialysis. Blood samples were taken 3 h post-dose, at the beginning, 3 h after the beginning and at the end of three dialysis sessions. Postfilter blood samples and dialysate samples were taken 3 h after the beginning of the dialysis on two occasions. Samples were taken from day 1-7 of lenalidomide first cycle. Written patient's consent was obtained. Plasma and dialysate concentrations were determined by validated ultra high-performance liquid chromatography with tandem mass spectrometric detection (uHPLC-MS/ MS) [3] .
Pharmacokinetics parameters
A one-compartment pharmacokinetic (PK) model was developed to predict plasma concentrations of lenalidomide during HCO dialysis, using published lenalidomide PK parameters, the patient's renal status on admission and the dialysis settings [2, 4, 5] . A PK model was built up initially without taking into account our observations and then compared to the observed plasma concentrations, to check whether they were consistent with the model. Detailed information about model development is available as Online Resource 1.
The model was further refined in order to improve the model fit and to obtain a likely description of lenalidomide concentrations between and during HCO dialysis sessions (Fig. 1) . The model was implemented and optimized using Microsoft Excel 2007 (Microsoft Corp., Redmond, WA, USA) with the Solver™ add-on.
Results
The estimated AUC 24h amounted to 3273 µg h/L for a dosage of 5 mg b.i.d. (Table 1) . Lenalidomide extraction coefficient (E) was 53% during the first HCO dialysis and 23% during the second one (Table 1) . These values are consistent with both our initial estimation based on drug's fraction unbound (f u ) and blood-to-plasma concentration ratio (r bp ) of f u · r bp (43%) and data already published during intermittent hemodialysis [2] . Differences in the measured value of E are likely to derive from both variability in dialysis performance and cumulated imprecision on pre-and post-filter determinations. Patient's lenalidomide PK parameters during HCO dialysis are detailed in Table 1 .
Discussion
Little is still known about drug disposition during HCO dialysis. Chen et al. [2] demonstrated that a 4-h conventional dialysis eliminates 31% of lenalidomide. HCO dialysis sessions of 8 h' duration, 5 days a week, with a blood flow of 300-350 mL/min and high filter permeability may result in a higher lenalidomide clearance compared to classical intermittent dialysis. Furthermore, HCO dialysis leads to significant albumin loss (5-10 g/h), which might alter free drug fraction and therefore drug clearance [6] . Altered free drug fraction might, however, be somewhat mitigated by albumin substitution during HCO dialysis [7] .
According to our initial evaluation, we would have expected a significant decrease in lenalidomide concentrations during the second half of the HCO dialysis. Nevertheless, measured lenalidomide concentrations showed that lenalidomide total clearance was still rather low. Dialytic clearance during HCO dialysis was similar to published data during conventional dialysis [2] . Our estimation of the AUC 24h (3273 µg h/L) obtained with 5 mg b.i.d. (once before and once after dialysis) was about 60% higher than the value expected in normal conditions (2057 µg h/L for a dosage of 25 mg q.d. at steady state). Actually, we estimated that about 85% of the dose administered before dialysis was eliminated in the effluent during the session. Still, an increase in AUC 24h (2476 µg h/L, +20%) was predicted for a single daily dosage of 5 mg given after dialysis in the same conditions. Predicted lenalidomide concentrations under 5 mg q.d. were similarly close to zero at the end of the dialysis, as predicted in normal conditions (Fig. 1) and supported actual guidelines for multiple myeloma which recommend 5 mg q.d. after dialysis for patients with terminal renal failure [1, 8] .
With this rational PK approach, we were able to conclude a posteriori that increasing the dosage of lenalidomide before HCO dialysis was not necessary for this patient and could potentially have led to increased toxicities. However, it was well tolerated and produced a good hematological response in this patient. The immunomodulatory effect of lenalidomide was recently linked to the degradation of transcriptional suppressors, which repress interleukin-2 expression and T cell activation [9] . Time-dependent degradation of these transcriptional factors was observed after both lenalidomide and pomalidomide treatment. These data suggest that response is probably related to exposure and hence to AUC. Even though therapeutic intervals are not defined yet, lenalidomide might be a forthcoming candidate for therapeutic drug monitoring. 
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In conclusion, we report here about disposition of lenalidomide during HCO dialysis in a patient with advanced multiple myeloma and terminal renal failure. Our model suggests that lenalidomide exposure under a dosage of 5 mg b.i.d. before and at the end of HCO dialysis led to higher lenalidomide exposure compared to normal conditions, without toxicity in this patient. According to our model, an increased dosage does not seem necessary for HCO dialysis compared to classical intermittent dialysis. A dosage of 5 mg q.d. at the end of HCO dialysis sessions is predicted to ensure an exposure comparable to normal conditions. Lenalidomide dosage during HCO dialysis remains yet to be prospectively validated in further studies.
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